Shandong Boan Biotechnology Co., Ltd. develops, manufactures, and commercializes biologics in Mainland China and internationally. Its commercialized products include Boyounuo (BA1101) bevacizumab injection for the treatment of metastatic or recurrent non-small cell lung cancer (NSCLC), recurrent glioblastoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer; and Boyoubei BA6101, a human immunoglobulin G2 monoclonal antibody for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The company develops BA1102 denosumab injection to treat patients with skeletal-related events caused by multiple myeloma and bone metastases from solid tumors, as well as giant cell tumour of bone; BA5101 dulaglutide injection indicated for glycemic control in adults with type-2 diabetes; and BA9101 aflibercept intravitreous injection to treat neovascular wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinopathy of prematurity. It also develops BA1104 to treat patients with melanoma, NSCLC, malignant pleural mesothelioma, RCC, classical hodgkin lymphoma, SCCHN, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal and gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma; BA2101, a human monoclonal antibody that targets interleukin-4 receptor subunit alpha; BA1202, a CEA/CD3 bispecific antibody; BA1106, a non-IL-2 blocking anti-CD25 antibody; BA1301: an antibody drug conjugate (ADC) candidate that targets Claudin 18.2; BA1105, a recombinant anti-Claudin 18.2 fully human IgG1 monoclonal antibody; and BA1302, a novel CD228-directed ADC. The company was founded in 2013 and is headquartered in Yantai, China. Shandong Boan Biotechnology Co., Ltd. is a subsidiary of Shandong Luye Pharmaceutical Co., Ltd. Address: No. 39 Keji Avenue, Yantai, China